(Dow Jones)--Amgen Inc. (AMGN) reported on Monday a disappointing fourth-quarter profit but said revenue and net income should both grow substantially in 2010. Amgen also said it had submitted information requested by the Food and Drug Administration for its experimental bone drug denosumab, which the agency declined to approve for osteoporosis in October. The focus of the Thousand Oaks, Calif., biotech giant remains on getting that drug to market as it is key to future growth.
